Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy Theravance Inc (THRX)?

Page 1 of 2

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always available for the general crowd. This doesn’t mean that they don’t have occasional colossal losses; they do (like Ackman’s recent Valeant losses). However, it is still good idea to keep an eye on hedge fund activity. With this in mind, as the current round of 13F filings has just ended, let’s examine the smart money sentiment towards Theravance Inc (NASDAQ:THRX).

Is Theravance Inc (NASDAQ:THRX) a bargain? Investors who are in the know are becoming hopeful. The number of bullish hedge fund bets advanced by 9 in recent months. At the end of this article we will also compare THRX to other stocks including Veeco Instruments Inc. (NASDAQ:VECO), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Lifelock Inc (NYSE:LOCK) to get a better sense of its popularity.

Follow Innoviva Inc. (NASDAQ:INVA)
Trade (NASDAQ:INVA) Now!

With all of this in mind, let’s analyze the new action surrounding Theravance Inc (NASDAQ:THRX).

How have hedgies been trading Theravance Inc (NASDAQ:THRX)?

At Q3’s end, a total of 20 of the hedge funds tracked by Insider Monkey were long this stock, a change of 82% from the second quarter. With hedgies’ sentiment swirling, there exists a select group of key hedge fund managers who were boosting their stakes meaningfully (or already accumulated large positions).

Of the funds tracked by Insider Monkey, Seth Klarman’s Baupost Group has the number one position in Theravance Inc (NASDAQ:THRX), worth close to $142.3 million, amounting to 2.4% of its total 13F portfolio. Coming in second is Iridian Asset Management, led by David Cohen and Harold Levy, holding a $89.8 million position; the fund has 0.8% of its 13F portfolio invested in the stock. Remaining peers that hold long positions consist of Michael A. Price and Amos Meron’s Empyrean Capital Partners, Jamie Zimmerman’s Litespeed Management and Richard Perry’s Perry Capital.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!